Empagliflozin in heart failure with preserved ejection fraction: first success in mission impossible

Heart failure and preserved ejection fraction (EF) is a common disease with a poor prognosis and increasing prevalence in the community. The current treatment paradigm includes symptomatic therapy, such as diuretics, risk factor control, and treatment of comorbidities. According to the most recent E...

Descripción completa

Detalles Bibliográficos
Autores principales: Sciatti, Edoardo, Gori, Mauro, D’elia, Emilia, Iacovoni, Attilio, Senni, Michele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
CCC 2022 - State of the Art Cardiology Supplement Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9653132/
https://www.ncbi.nlm.nih.gov/pubmed/36380802
http://dx.doi.org/10.1093/eurheartjsupp/suac106

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9653132/
https://www.ncbi.nlm.nih.gov/pubmed/36380802
http://dx.doi.org/10.1093/eurheartjsupp/suac106

Ejemplares similares